STOCK TITAN

Xilio Therapeutics (XLO) Stock Price, News & Analysis

XLO NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
21 252 sessions, November 14, 2025 to November 16, 2026
Largest daily move
+13.5% close of May 14, 2026
1-year change
-22.2% closing prices, November 14, 2025 to November 16, 2026
1-month change
-9.9% closing prices, October 16, 2026 to November 16, 2026

Company Description

Xilio Therapeutics, Inc. (Nasdaq: XLO) is a clinical-stage biotechnology company focused on discovering and developing tumor-activated, or "masked," immuno-oncology (I-O) therapies for people living with cancer. According to the company’s public disclosures, its goal is to significantly improve outcomes for patients without the systemic side effects that can limit current I-O treatments. Xilio is advancing a pipeline of novel, tumor-activated molecules designed to localize anti-tumor activity within the tumor microenvironment and optimize the therapeutic index of potent immune-modulating agents.

Xilio states that it is leveraging a proprietary masking technology and tumor-activation platform to develop multiple classes of masked I-O therapies. These include tumor-activated cytokines, antibodies and immune cell engagers that are intended to remain largely inactive in healthy tissues and become activated in the tumor microenvironment. By harnessing protease activity and other features of the tumor microenvironment, the company aims to widen the therapeutic window for powerful immunotherapies that might otherwise cause dose-limiting toxicities when given systemically.

Core Pipeline and Programs

Based on the company’s recent press releases and SEC filings, Xilio’s pipeline includes several key investigational programs:

  • Vilastobart: an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. Vilastobart is designed to block CTLA-4 and deplete regulatory T cells when activated in the tumor microenvironment. It is being evaluated in a multi-center, open-label Phase 1/2 clinical trial in combination with atezolizumab (Tecentriq) in patients with advanced solid tumors and in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC), including those without liver metastases. Xilio has reported Phase 2 data in MSS mCRC, including objective responses in heavily pretreated patients without liver metastases and with high plasma tumor mutational burden, as well as data suggesting potential roles for plasma tumor mutational burden (TMB) and circulating tumor DNA (ctDNA) as biomarkers of response.
  • Efarindodekin alfa (XTX301): an investigational tumor-activated interleukin-12 (IL-12) designed to stimulate anti-tumor immunity and reprogram poorly immunogenic "cold" tumors toward an inflamed or "hot" state. Efarindodekin alfa is being evaluated as a monotherapy in an ongoing first-in-human, multi-center, open-label Phase 1/2 clinical trial in patients with advanced solid tumors. Xilio has reported Phase 1 data showing monotherapy anti-tumor activity, including partial responses in heavily pretreated patients, and a safety profile that has allowed dosing at levels substantially higher than the maximum tolerated dose reported for recombinant human IL-12. The company has initiated patient dosing in the Phase 2 portion of this trial.
  • XTX501: a novel, tumor-activated bispecific PD-1 / masked IL-2 molecule. Xilio describes XTX501 as designed to selectively stimulate PD-1 positive, antigen-experienced T cells and enhance their function, with masking intended to overcome IL-2 receptor–mediated clearance and peripheral activity. In preclinical studies disclosed by the company, XTX501 demonstrated monotherapy activity, including in settings insensitive to PD-1, and tumor-selective pharmacodynamics consistent with its intended mechanism. XTX501 is advancing through investigational new drug (IND)-enabling studies with plans to submit an IND application.
  • Masked T cell engager programs: Xilio is using its tumor-activation platform to develop multiple preclinical masked T cell engager programs. These include wholly owned programs targeting tumor-associated antigens such as PSMA, CLDN18.2 and STEAP1, and an additional program under a collaboration with AbbVie. The company has described two proprietary engager formats: the tumor-activated cell engager (ATACR) format, a bispecific T cell engager with a masked CD3 targeting domain, and the selective effector-enhanced cell engager (SEECR) format, a tri-specific design that adds co-stimulatory signaling. Preclinical data presented by Xilio indicate that these masked T cell engagers can demonstrate potent anti-tumor activity with evidence of reduced systemic toxicity in murine models and that incorporation of co-stimulation in the SEECR format can enhance durability of T cell activation.

Masking Technology and Tumor Microenvironment Focus

Across its programs, Xilio emphasizes a consistent design principle: tumor-activated masking intended to localize activity within the tumor microenvironment. For vilastobart, this approach is intended to enable CTLA-4 blockade and regulatory T cell depletion primarily in tumors, with the goal of reducing immune-related adverse events such as colitis that have historically limited systemic anti-CTLA-4 therapies. For efarindodekin alfa, the masked IL-12 design is intended to induce interferon gamma signaling, immune cell infiltration and upregulation of PD-1 and PD-L1 within tumors, while limiting systemic exposure associated with IL-12 toxicity.

For its masked T cell engager platform, Xilio reports that it leverages protease activity in the tumor microenvironment so that CD3-directed T cell engagement is preferentially activated in tumors. According to the company’s preclinical presentations, this design has shown potential to expand the therapeutic window relative to non-masked T cell engagers and to reduce systemic toxicity signals in animal models. The SEECR format adds co-stimulatory signaling to further enhance potency and durability of T cell responses in these models.

Strategic Collaborations and Partnerships

Xilio has entered into several collaborations with larger biopharmaceutical companies, as described in its news releases and SEC filings:

  • Gilead Sciences: In March 2024, Xilio entered into an exclusive global license agreement with Gilead to develop and commercialize efarindodekin alfa and specified other molecules directed to IL-12. Xilio is responsible for clinical development of efarindodekin alfa through the initial Phase 2 portion of the ongoing Phase 1/2 trial. Following delivery of a specified clinical data package, Gilead may elect to assume development and commercialization responsibilities, subject to a transition fee and potential development, regulatory and sales-based milestone payments and royalties, as described in Xilio’s public disclosures.
  • Roche: Xilio has a co-funded clinical trial collaboration with Roche to evaluate vilastobart in combination with atezolizumab in a multi-center, open-label Phase 1/2 clinical trial in patients with advanced solid tumors and MSS metastatic colorectal cancer.
  • AbbVie: Xilio has disclosed a collaboration, license and option agreement with AbbVie related to a masked antibody-based immunotherapy program and a masked T cell engager program. The company has reported achieving a development milestone under this agreement and is advancing a collaborative masked T cell engager program alongside its wholly owned PSMA, CLDN18.2 and STEAP1 programs.

Capital Markets and Listing Status

Xilio’s common stock trades under the symbol XLO. According to a Form 8-K filed on October 2, 2025, the company received approval from Nasdaq to transfer the listing of its common stock from The Nasdaq Global Select Market to The Nasdaq Capital Market, effective October 6, 2025, while continuing to trade under the same ticker. In that filing, Xilio noted prior notifications from Nasdaq regarding the minimum bid price requirement and stockholders’ equity requirements for continued listing and disclosed that it had been granted an additional grace period to regain compliance with the minimum bid price requirement.

The company has also reported follow-on public offerings, warrant financings and warrant exercises, as well as the adoption of equity incentive plans and option repricings approved by stockholders, as part of its approach to funding operations and advancing its pipeline. In January 2026, Xilio disclosed that it had received gross proceeds from the exercise of Series B warrants and estimated a cash and cash equivalents balance as of the end of 2025, extending its projected cash runway based on its then-current operating plans.

Clinical and Scientific Focus Areas

The company’s disclosures highlight several scientific and clinical themes across its programs:

  • Biomarker-driven development: For vilastobart in MSS mCRC, Xilio has reported data supporting the potential use of plasma-based tumor mutational burden as a predictive biomarker for response to treatment with vilastobart in combination with atezolizumab, and data suggesting that ctDNA reductions may serve as an early indicator of response.
  • Cold-to-hot tumor conversion: For efarindodekin alfa, Xilio describes pharmacodynamic data showing sustained interferon gamma signaling, increased T cell infiltration and transformation of the tumor microenvironment toward an inflamed state, consistent with IL-12 biology.
  • Masked T cell engagement: For its masked T cell engager programs, the company emphasizes preclinical evidence that masking and tumor-selective activation can provide potent anti-tumor activity with reduced systemic toxicity in animal models, and that co-stimulatory signaling in the SEECR format can enhance the durability of anti-tumor responses.

Corporate Governance and Stockholder Matters

Xilio is incorporated in Delaware and files periodic reports, proxy statements and current reports with the U.S. Securities and Exchange Commission. In 2025, the company filed a definitive proxy statement for a special meeting of stockholders to consider, among other items, approval of a one-time repricing of certain outstanding employee stock options and approval of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan. Subsequent Form 8-K filings report that stockholders approved these proposals and that the option repricing was implemented.

The company has also disclosed changes in board leadership, including the appointment of a new chair of the board of directors following the retirement of the prior chair. These governance updates are described in its press releases and related Form 8-K filings.

Position Within Biotechnology and Immuno-Oncology

Within the broader biotechnology and immuno-oncology landscape, Xilio characterizes itself as a company focused on tumor-activated, or masked, therapies designed to address limitations of existing systemic immunotherapies. Its programs span checkpoint modulation (anti-CTLA-4), cytokine therapy (IL-12), bispecific PD-1/IL-2 molecules and masked T cell engagers targeting defined tumor-associated antigens. The company’s public communications emphasize the potential for its masking technology and tumor-activation platform to be applied across multiple modalities and targets.

Investors and observers can follow Xilio’s progress through its clinical trial disclosures, scientific presentations at meetings such as the Society for Immunotherapy of Cancer (SITC) and the American Society of Clinical Oncology (ASCO), press releases on pipeline and business updates, and SEC filings that provide additional detail on collaborations, financings and corporate actions.

Stock Performance

$7.70
-4.64%
-0.37
Last updated: November 16, 2026 at 16:00
-22.2%
Performance 1 year
$54.4M

Xilio Therapeutics (XLO) closed at $7.70 on November 16, 2026. Over the past 12 months, the price has lost 22.2%.

See what a $1,000 investment in XLO would be worth today

Average down calculator for XLO

XLO Metrics & Rankings

Price returns through November 16, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Financial Highlights

Xilio Therapeutics generated $43.8M in revenue in FY2025, operating income reached -$42.0M (-95.9% operating margin), and net income was -$35.0M, reflecting a -80.0% net profit margin. Diluted earnings per share stood at -$4.19. The company generated -$5.0M in operating cash flow. The current ratio was 2.58, measuring current assets divided by current liabilities.

$43.8M
Revenue (FY2025)
-$35.0M
Net Income (FY2025)
-$5.0M
Operating Cash Flow

Upcoming Events

YEAR
2026
2026 Financial

Warrant exercise deadline

Deadline to exercise Series B and C warrants at $0.75 per share
H1
2027
H1 2027 Corporate

Efarindodekin data delivery

Delivery of efarindodekin alfa option data package to Gilead expected in H1 2027; partnership milestone may trigger options.
YEAR
2027
2027 Regulatory

IND submission planned

Company plans IND submission for XTX601 in 2027; will conduct IND‑enabling studies beforehand. No date or site provided.
MAR
01
March 1, 2027 Corporate

25% options vest

One-year cliff: 25% of the granted 50,050 options vests
APR
01
April 1, 2027 Corporate

25% vesting anniversary

25% of granted options vest on first anniversary of employment
APR
01
April 1, 2027 - April 1, 2030 Corporate

Monthly vesting period

Remaining 75% vests in 36 equal monthly installments following first anniversary
MAY
01
May 1, 2027 Corporate

25% vests

Cliff vest: 25% of the 1,982-share option vests; $8.32 exercise price; subject to continued service and plan terms.
MAY
01
May 1, 2027 - May 1, 2030 Corporate

Monthly vesting period

Monthly vesting: remaining 75% vests monthly over 36 months from 2027-05-01 through 2030-05-01; 1,982 shares total.
H2
2027
H2 2027 Clinical

Initial Phase 1 data readout

Initial Phase 1 data for XTX501 expected in H2 2027; subject to FDA clearance.
H2
2027
H2 2027 Clinical

T‑cell engager INDs

IND submissions planned for masked T‑cell engager programs targeting CLDN18.2 and PSMA+STEAP1 in H2 2027.
Q4
2027
Q4 2027 Clinical

Initial Phase 1 Data

Xilio expects to report initial Phase 1 clinical data for XTX501 during Q4 2027; topline results timing subject to trial progress.
Q4
2027
Q4 2027 Clinical

XTX501 Phase 1 data

Initial XTX501 Phase 1 data readout in metastatic NSCLC expected in Q4 2027; potential clinical impact and investor webcast.
Q4
2027
Q4 2027 Regulatory

XTX602 IND filing

Planned investigational new drug (IND) submission for XTX602 in Q4 2027; regulatory milestone for clinical start.
Q4
2027
Q4 2027 Regulatory

XTX701 IND filing

Planned investigational new drug (IND) submission for XTX701 in Q4 2027; prepares program for human studies.
MAR
01
March 1, 2030 Corporate

Final options vesting

Remaining 75% vests in 36 monthly installments; full vesting completes
APR
01
April 1, 2036 Corporate

Option expiration date

10-year term ends; granted options from 2026 grant expire
MAY
01
May 1, 2036 Corporate

Option expiration

Option expiration: ten-year term ends on 2036-05-01; option exercisable at $8.32 per share until expiry.
OCT
01
October 1, 2036 Corporate

Option Expiration Date

Employee stock options granted effective 2026-10-01 have a ten-year term and expire on 2036-10-01 per the grant agreements.

Xilio Therapeutics has 18 upcoming scheduled events. The next event, "Warrant exercise deadline", is expected in 2026. 1 of them is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the XLO stock price.

Short Interest History

Last 12 Months

Short interest in Xilio Therapeutics (XLO) currently stands at 382.8 thousand shares, down 4.4% from the previous reporting period, representing 8.8% of the float. Since the latest stock split, short interest has increased by 119.6%, measured from April 2026.

Days to Cover History

Last 12 Months

Days to cover for Xilio Therapeutics (XLO) currently stands at 20.3 days, down 50.7% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 1.8 to 44.5 days.

XLO Company Profile & Sector Positioning

Xilio Therapeutics (XLO) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing XLO often look at related companies in the same sector, including Rani Therapeutics Holdings, Inc. (RANI), Boundless Bio, Inc. (BOLD), Verrica Pharmaceuticals Inc. (VRCA), XBiotech Inc (XBIT), and Heron Therapeutics, Inc. (HRTX). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate XLO's relative position within its industry.

Frequently Asked Questions

The current stock price of Xilio Therapeutics (XLO) is $7.70 as of November 16, 2026.

The market cap of Xilio Therapeutics (XLO) is approximately $54.4M. Learn more about what market capitalization means .

The FY2025 revenue of Xilio Therapeutics (XLO) is $43.8M, from its most recent completed fiscal year.

The FY2025 net income of Xilio Therapeutics (XLO) is -$35.0M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Xilio Therapeutics (XLO) is -$4.19 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Xilio Therapeutics (XLO) is -$5.0M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Xilio Therapeutics (XLO) is -80.0% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Xilio Therapeutics (XLO) is -95.9% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The current ratio of Xilio Therapeutics (XLO), current assets divided by current liabilities, was 2.58 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Xilio Therapeutics (XLO) is -$42.0M for FY2025, its most recent completed fiscal year. Learn about operating income.

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company that discovers and develops tumor-activated, or masked, immuno-oncology therapies. According to its public disclosures, the company’s goal is to improve outcomes for people living with cancer by localizing potent immune activity within the tumor microenvironment and reducing systemic side effects associated with current immunotherapies.

Xilio describes its proprietary masking technology as a tumor-activation approach that keeps potent immuno-oncology agents largely inactive in healthy tissues and activates them in the tumor microenvironment. For example, its masked antibodies, cytokines and T cell engagers are designed to be unmasked by tumor-associated protease activity, with the aim of widening the therapeutic window and limiting systemic toxicity.

Based on company disclosures, Xilio’s main clinical programs include vilastobart, an investigational tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody being studied in combination with atezolizumab in advanced solid tumors and MSS metastatic colorectal cancer, and efarindodekin alfa (XTX301), an investigational tumor-activated IL-12 being evaluated as a monotherapy in an ongoing Phase 1/2 trial in patients with advanced solid tumors.

Efarindodekin alfa (XTX301) is described by Xilio as a tumor-activated IL-12 intended to potently stimulate anti-tumor immunity and reprogram the tumor microenvironment of poorly immunogenic “cold” tumors toward an inflamed or “hot” state. In Phase 1 data reported by the company, efarindodekin alfa has shown monotherapy anti-tumor activity and pharmacodynamic effects consistent with IL-12 biology, while being administered at doses higher than those historically tolerated for recombinant human IL-12.

Xilio reports that it is advancing multiple preclinical masked T cell engager programs targeting tumor-associated antigens such as PSMA, CLDN18.2 and STEAP1, along with a collaborative program with AbbVie. These programs use the company’s ATACR format, a bispecific T cell engager with a masked CD3 domain, and its SEECR format, a tri-specific design that adds co-stimulatory signaling. Preclinical data disclosed by Xilio indicate potent anti-tumor activity and evidence of reduced systemic toxicity in animal models.

Xilio has publicly announced several collaborations. It has an exclusive global license agreement with Gilead Sciences for efarindodekin alfa and other IL-12–directed molecules, under which Xilio conducts early clinical development and Gilead holds an option to assume later-stage development and commercialization. The company also has a co-funded clinical trial collaboration with Roche to evaluate vilastobart in combination with atezolizumab, and a collaboration, license and option agreement with AbbVie related to a masked antibody-based immunotherapy program and a masked T cell engager program.

According to a Form 8-K filed on October 2, 2025, Xilio Therapeutics’ common stock is listed on The Nasdaq Capital Market under the ticker symbol XLO. The company previously traded on The Nasdaq Global Select Market and received approval to transfer its listing while retaining the same trading symbol.

In 2025, Xilio disclosed that it had received Nasdaq deficiency letters regarding the $1.00 minimum bid price requirement and the minimum stockholders’ equity requirement for continued listing on The Nasdaq Global Select Market. The company later reported that Nasdaq approved a transfer of its listing to The Nasdaq Capital Market and granted an additional grace period to regain compliance with the minimum bid price requirement, as described in its Form 8-K filings.

Xilio’s disclosures highlight the use of plasma-based tumor mutational burden (TMB) and circulating tumor DNA (ctDNA) as potential biomarkers in its vilastobart program for MSS metastatic colorectal cancer. The company has reported Phase 2 data indicating that high plasma TMB may be associated with higher response rates to vilastobart in combination with atezolizumab, and that deep reductions in ctDNA can precede radiographic responses and correlate with clinical outcomes in certain patients.

No. Xilio describes itself as a clinical-stage biotechnology company. Its product candidates, including vilastobart and efarindodekin alfa, are investigational, have not been approved by any regulatory agency, and their safety and efficacy have not been established for any indication.